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We have entered a new era in HIV prevention whereby priorities have expanded from biomedical discovery to include 
implementation, eﬀ ectiveness, and the eﬀ ect of combination prevention at the population level. However, gaps in 
knowledge and implementation challenges remain. In this Review we analyse trends in the rapidly changing landscape 
of HIV prevention, and chart a new path for HIV prevention research that focuses on the implementation of eﬀ ective 
and eﬃ  cient combination prevention strategies to turn the tide on the HIV pandemic.
Introduction
Until recently, HIV prevention lacked credibility with 
data from prevention trials showing little or no decrease 
in incident HIV.5 Furthermore, when successes were 
made public,6–8 explanations were often conﬂ icting and 
lessons for application to other settings unclear. However, 
the past year marked the end of this steady stream of 
disappointing results, and a concomitant change is 
evident in public perception and the opinions of policy 
makers. The discourse on HIV prevention now includes 
the possibility that the epidemic can be stopped.9
Increasingly scarce ﬁ nancial resources also drive this 
renewed focus on prevention. The global economic crisis 
has substantially aﬀ ected funding for HIV, with resources 
for prevention levelling oﬀ  in the past decade and future 
funding commitments unclear.10 These reductions put 
many programmes at risk and warrant a sharpened focus 
on prevention. Fiscal constraints have created pressure 
on prevention program mes to be more accountable by 
providing clearer evidence of impact and delivering better 
value for money.
We review developments in HIV prevention from the 
past 3 years (since The Lancet Series on HIV prevention 
in 20082–4), with particular emphasis on gaps in knowledge 
and a focus on what are now the most salient prevention 
issues: discovery in the continued search for vaccines 
and a cure; new challenges related to antiretroviral-based 
prevention; implementation challenges that preclude 
scale-up of prevention strategies known to be eﬀ ective — 
speciﬁ cally, HIV testing, voluntary medical male 
circumcision (VMMC), and prevention of mother-to-
child transmission (PMTCT); and progress on and 
challenges for structural and behavioural interventions.
Vaccines and the search for a cure  
Strategies for vaccine development include innate, cell-
mediated, or antibody-mediated resistance to infection, or 
all three.11 Successful modiﬁ cation of HIV in Rhesus 
macaque monkeys led to increased focus on cell-mediated 
immunity;12 however, the STEP trial13 (using immunogens 
that worked in macaques) showed neither protection from 
HIV nor alteration in viral replication in vaccine recipients, 
but did stimulate an immune response that exerted 
pressure on the virus acquired.14 In a trial in Thailand15 a 
canarypox vector vaccine (ALVAC-HIV) boosted with a 
recombinant glycoprotein vaccine (AIDSVAX B/E) led to a 
31% reduction of HIV incidence in vaccine recipients. The 
immune responses that enabled protection are a focus of 
intensive post-trial studies, including consideration of 
non-neutralising antibodies that function via antibody-
dependent cellular cytotoxic eﬀ ects (ADCC).16,17
Renewed interest18 in curing HIV was partly stimulated 
by a report of a bone-marrow transplant of CCR5-deleted 
stem cells to an HIV-positive patient, who seemed to 
eliminate detectable HIV after engraftment of this tissue.19 
This result conﬁ rmed the importance of the CCR5 
receptor for HIV replication, and galvanised experiments 
focused on gene therapy to modify this receptor, to date 
conducted ex vivo and in a mouse model.20 Investigators 
committed to curing AIDS have further divided this work 
into immunomodiﬁ cation21 and the use of antiretroviral 
drugs to eliminate all HIV-infected cells.22 For both 
approaches, the latent reservoir of HIV-infected T cells is 
the greatest challenge. At the start of HIV infection, the 
virus is integrated into host DNA, and cells become 
quiescent and allow HIV replication at a very low rate, 
even with antiretroviral therapy (ART).23 However, when 
ART is discontinued, viral load returns to a level recorded 
before therapy. A novel class of cancer drugs designed to 
Search strategy and selection criteria
We covered several topics in HIV prevention (biomedical, behavioural, structural) that 
together comprise combination prevention.1 We focused on randomised trials, rigorous 
observational studies, and systematic and meta-reviews completed since The Lancet Series 
on HIV prevention in 2008.2–4 The most recent reviews5 were used as a starting point. We 
searched PubMed and Medline for papers published in peer-reviewed journals since 2008, 
and electronic conference proceedings of recent HIV/AIDS-related conferences up to the 
end of April, 2011. We also reviewed relevant publications and websites from international 
organisations, including UNAIDS and WHO, and non-governmental organisations and 
advocacy groups involved in HIV prevention research. Search terms included “HIV”, 
“prevention”, “antiretroviral therapy (ART)”, “vaccines”, “behavior”, “HIV testing”, “male 
circumcision”, “microbicides”, “mother-to-child transmission (MTCT)”, “implementation 
science”, and “operations research”. Because the eﬀ ectiveness of a single intervention was 
not the objective of the review, systematic review methods were not used. The goal was 
instead to broadly review existing prevention interventions and identify salient issues, 
research needs, and gaps in knowledge.
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force replication in each infected cell in the latent pool (so 
traditional ART can work) is now entering clinical trials.22
An alternative to eradication of HIV is a so-called 
functional cure of infection that is evoked by stimulation 
of T cells to restrict HIV replication in the absence of 
antiretroviral drugs. Intensive studies of the HIV response 
to T cells in acute infection,24 and of the few patients whose 
immune systems control HIV,25 suggest the feasibility of 
this approach with a combination of immunogenic 
proteins (a therapeutic vaccine), immuno stimulatory 
cytokines, and other novel forms of immune modiﬁ cation 
of the virus by reactive T cells.26 Patients treated very early 
might have a smaller pool of latent virus, and might 
therefore be good candidates for such curative therapy.22
Product development and proof-of-concept studies are 
important areas in the search for HIV vaccines and a 
cure. The next phase of vaccine research will focus on 
development of immunogens that allow the HIV-negative 
recipient to form durable neutralising antibodies.27 
Protection of Rhesus macaques from simian immuno-
deﬁ ciency virus (SIV) was possible with the passive 
infusion of monoclonal antibodies that neutralise SIV.28 
Additionally, Stamatatos and colleagues29 and Tomaras 
and colleagues30 described the detection of very broad 
and potent neutralising antibodies in a patient with HIV 
infection. However, such antibodies are generated too 
late to aﬀ ect the disease.27 These ﬁ ndings could facilitate 
the design of a vaccine that leads to secretion of high 
concen trations of protective antibodies in the genital 
tract, whether neutralising or ADCC.11,16 Another 
innovative approach is passive immunisation, either by 
direct admini stration of broadly neutralising antibodies, 
or by use of gene transfer technology to achieve sustained 
production of antibodies. In the search for a cure, 
experiments using vaccination, maximal ART, and 
adjunctive cytokines are in progress, and are the subject 
of the Martin Delaney cure award.31–33
Prevention based on antiretroviral drugs
Pre-exposure prophylaxis
Concerted and ongoing eﬀ orts aim to understand the 
penetration of antiretroviral drugs into the male and 
female genital tract, and the protective eﬀ ects of oral or 
topical (ie, microbicide) pre-exposure drugs on HIV 
acquisition.34 The ﬁ rst results were reported in 2010, in the 
CAPRISA 004 study in South Africa.35 889 high-risk 
women used an applicator that delivered 1% tenofovir gel 
into the vaginal vault up to 12 h before, and within 12 h 
after, intercourse. Investigators reported a 39% reduction 
in overall acquisition of HIV, and maximum reduction 
was 54% in the most adherent women. HIV acquisition 
was inversely correlated with detection of tenofovir in the 
vaginal secretions—an indication of the strong association 
between product adherence and eﬃ  cacy. An ongoing trial36 
further examines these results by examining daily use of 
gel and oral pre-exposure prophylaxis, and compares these 
regimens with placebo. Tenofovir gel also inhibits 
replication of herpes simplex virus-2 (HSV-2), and reduced 
acquisition of this virus was noted in CAPRISA.35
Eight trials with oral antiretroviral agents for pre-
exposure prophylaxis are currently ongoing,37 using 
antiviral agents that proved protective in a macaque 
model.38 In the iPrEx study in 2010,39 HIV-negative men 
who have sex with men were given daily emtricitabine 
and tenoﬁ vir disoproxil fumarate (TDF plus FTC) for up 
to 2·8 years. This antiretroviral combination was selected 
because it oﬀ ered the greatest protection to Rhesus 
macaques in a model of rectal exposure.38 The study 
recorded a 44% reduction in HIV acquisition and, as with 
CAPRISA,35 eﬃ  cacy was strongly associated with 
concentrations of antiretroviral drug, which is a direct 
marker of adherence. Some study participants had mild 
renal dysfunction or decrease in bone mineral density, 
and two who had unrecognised acute (seronegative) HIV 
infection on pre-exposure prophylaxis developed a 
antiretroviral-resistant variant. By contrast, the FEM-PrEP 
trial of TDF plus FTC oﬀ ered to high-risk women was 
discontinued because an equal number of infections 
occurred in both the placebo and treatment groups.40 The 
precise explanation for the diﬀ erence between the IPrEx 
and FEM-PrEP results is unknown; however, a strong 
possibility is that the concentration of tenofovir in the 
female genital tract is insuﬃ  cient to prevent HIV 
acquisition.41,42 These results do not diminish the potential 
for oral pre-exposure prophylaxis, but recommendation 
of wide-scale promotion for women would be premature.
Treatment for prevention
Treatment for prevention describes the public health or 
community beneﬁ ts from the use of ART to decrease 
onward transmission of HIV.43 The biological mechanism 
is that treatment reduces viral load and thus reduces 
infectiousness.44 Five observational reports noted sub-
stantial reduction of HIV transmission to a sexual partner 
when the HIV-infected index case was given ART.45 The 
HPTN 052 study46 is a randomised controlled trial that 
directly examines the ability of ART to interrupt HIV 
transmission from an index patient with HIV to his or her 
sexual partner. On April 28, 2011, the multinational Data 
Safety and Monitoring Board overseeing the study reported 
a substantial diﬀ erence in prevention and treatment 
outcomes related to early start of ART, and recommended 
that the randomisation study be ended. Findings from the 
study showed a 96% reduction of HIV transmission 
attributed to the use of antiretroviral drugs.47 
Some (but not all) results from mathematical modelling 
analyses lend support to the population-level use of 
treatment for prevention48,49 and suggest a greater beneﬁ t 
than that possible with pre-exposure prophylaxis.50 
Guidelines for HIV treatment support early start of ART,51 
which would also favour the public health potential of 
this approach, and several population-level pilot studies 
of antiretroviral drugs for prevention are now planned. 
Importantly, the HPTN 052 trial has bridged a crucial 
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gap by unequivocally showing that treatment for 
prevention is eﬃ  cacious.
Key research areas for prevention with antiretroviral 
drugs
The extent to which pre-exposure prophylaxis and ART 
reach individuals with the highest viral load is central to 
the success of prevention approaches based on antiretroviral 
drugs. The main challenge is whether the right people 
have the right drug concentrations of the right drugs at the 
right time.17 Hence, an important issue for both pre-
exposure prophylaxis and treatment for prevention is to 
establish eligibility, for which high and frequent uptake of 
HIV testing is a requisite. In treatment for prevention, the 
diﬃ  culty in detection of people with HIV infection who 
are asymptomatic has been well documented.52,53
Another approach is to emphasise ART access before 
the rise in viral load that typically occurs in late stages of 
infection, especially in patients with the highest viral 
loads54—eg, those with early infection who are the most 
infectious.17 Patients with acute and primary HIV 
infection have also been diﬃ  cult to identify, even though 
most are symptomatic.17 Although new diagnostic 
approaches might overcome some of these challenges,55 
the diﬃ  culty of linking asymptomatic people to care has 
been well documented.44,43,56
Another important issue, given challenges related to 
universal access, is how to prioritise distribution of 
antiretroviral drugs. Most agree that pregnant women in 
Africa and discordant couples are high-priority groups, 
but the need extends far beyond these groups. Moreover, 
the potential role of pre-exposure prophylaxis in these 
groups should be tempered by the ﬁ ndings of the FEM-
PrEP study.40 The most crucial issue for distribution is 
how to ensure that equity considerations are appropriately 
addressed in resource-poor settings when treatment is 
not available to all who need it.
The burden of adding antiretroviral-based prevention 
to already strained health systems remains to be 
determined. The frail health infrastructure of sub-
Saharan Africa, characterised by severe shortages in 
structural and human resources, is widely recognised as 
one of the main challenges in addressing the epidemic. 
To confront this issue, task shifting (ie, redistribution of 
tasks from highly trained health workers to those with 
less training, including non-professionals) is becoming 
more widespread.57,58 Such reorganisation also decentral-
ises health services (eg, to rural areas), reducing the travel 
burden to attend hospitals or clincs. Although task 
shifting is an eﬃ  cient strategy with many documented 
successes, it presents many challenges, including the 
provision of training and supervision that is suﬃ  cient to 
maintain quality and safety, and the need to address 
resistance from governments and health professionals. 
However, task shifting is not a substitute for much 
needed resources and invest ments in health systems 
throughout the area.
As is apparent from the CAPRISA35 and iPrEx39 trials, 
adherence is a key issue, and research continues to 
examine innovative real-time strategies to monitor 
adherence to ART that could increase the reliability of 
adherence measures while increasing uptake.59 
Development of interventions that are less dependent on 
adherence (eg, rings, implants, longacting antiretroviral 
drugs, and slow-release topical approaches) is one of the 
crucial challenges.60 Adherence is also a challenge for 
treatment for which approaches independent of 
adherence are needed. Research now aims to assess 
topical and systemic intervention products that diﬀ er 
from products used for treatment, well tolerated products, 
and the use of products for postexposure prophylaxis.61
Eﬀ ective prevention strategies dominated by 
implementation challenges
HIV testing
HIV testing is recognised as a crucial part of almost all 
programmes for HIV prevention, especially in view of new 
developments in prevention with antiretroviral drugs. 
Testing can identify people living with HIV/AIDS for the 
purpose of HIV prevention and care,56 and can also identify 
those who are HIV negative, who can then be prioritised 
for prevention interventions to help them to maintain their 
status (eg, pre-exposure prophylaxis, VMMC). This 
approach, whereby HIV testing is central to the prevention–
treatment continuum, moves away from general risk 
reduction messages for all audiences (eg, condom use, 
sexually transmitted infection [STI] treatment) towards 
speciﬁ cally tailored approaches for individuals based on 
their serostatus and prevention needs.
Although HIV testing—which has historically been 
combined with risk reduction counselling—can prevent 
inadvertent transmission to sexual and needle-sharing 
partners in people living with HIV/AIDS, this eﬀ ect is 
generally not noted in individuals who are HIV 
negative62,63 (although the community-level beneﬁ t of 
testing on prevention is being investigated in Project 
Accept64). Research is focused on streamlining the content 
of the testing process, particularly in response to the 
diminishing support for pre-test counselling, by moving 
assessments of individual risk and plans for risk 
reduction to post-test sessions.65,66 Hence, we refer to HIV 
testing alone as part of a large programme of combination 
prevention, which is intentionally disaggregated from a 
broad approach to HIV testing and counselling.
Much of the substantial scale-up in HIV testing67 has 
been attributable to worldwide recognition of the value 
of expanding testing from client-initiated testing 
(eg, voluntary counselling and testing) to routine testing,65 
which could normalise and destigmatise HIV testing.68 
Furthermore, such strategies are cost eﬀ ective,69 have 
individual clinical beneﬁ ts (via earlier detection),70 and 
could potentially greatly reduce new infections when 
coupled with early start of ART.49 However, successful 
implementation of so-called test-and-treat strategies are 
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challenged by the diﬃ  culties of testing of large numbers 
of healthy people who are not attending health-care 
services, incomplete engagement in HIV care,56 and 
inadequate technology to detect people with acute HIV 
infection who are the most infectious.17
The most crucial questions for HIV testing centre on 
identiﬁ cation of the best strategies to increase demand for 
and provision of testing services, in both individuals and 
couples. Overall coverage of testing is low—a median of 
17% of women and 14% of men in the general epidemics 
in sub-Saharan Africa from 2005 to 2009 had ever been 
tested for HIV infection and knew their results.71 Demand 
for HIV testing is a complex function of access to health 
care, perception of risk, fear, stigma, and the threat of 
violence.72–74 Although onsite rapid testing and provider-
initiated testing can overcome some of these obstacles, 
approaches to mitigate fear and the threat of violence 
(particularly for women) are being investigated. Similarly, 
models of service delivery to optimise uptake of testing 
and linkage to care and treatment, while protecting patient 
rights and conﬁ dentiality, are an active part of operations 
research. Home-based, door-to-door testing is a promising 
model,64,75 as are structural interventions, such as economic 
incentives,76 which can play an important enabling part. In 
this way, both supply-side and demand-side barriers as well 
as ineﬃ  ciencies can be addressed to improve access to and 
delivery of this key entry point to HIV prevention services.
Prevention of mother-to-child transmission 
WHO’s four-pronged strategy77 for PMTCT recommends: 
(1) primary HIV prevention in women of childbearing age; 
(2) prevention of unintended pregnancies in women with 
HIV infection; (3) prevention of HIV transmission from 
women with HIV to their infants via use of antiretroviral 
drugs; and (4) provision of treatment, care, and support to 
women with HIV and to their families. To date, most 
emphasis has been placed on the third prong (perhaps at 
the expense of the others)—the integrated cascade of 
services centred on antiretroviral drug use oﬀ ered in 
antenatal, perinatal, and postnatal care that together can 
reduce the risk of mother-to-child transmission to less than 
5% in breastfeeding populations and less than 2% in non-
breastfeeding populations.78,79 For maximum eﬀ ect, 
pregnant women who are HIV positive should receive a 
series of interventions, including attending antenatal care; 
being oﬀ ered, accepting, and receiving the results of a HIV 
test; and accepting and adhering to antiretroviral-drug 
prophylaxis for themselves and their exposed infant: the 
PMTCT cascade. Thus, the success of PMTCT programmes 
is highly sensitive to the cumulative impact of attrition of 
mother–infant pairs at each step. Only 15–30% of pairs in 
high-burden countries complete the cascade.80
In 2010, WHO revised the guidelines for PMTCT 
treatment in response to increased evidence about the 
improved eﬀ ectiveness of combination antiretroviral 
regimens compared with monotherapy (eg, single-dose 
nevirapine). The new guidelines recommended that all 
eligible pregnant women with HIV (ie, CD4 cell count 
≤350 cells per μL) receive lifelong antiretroviral therapy for 
their own health, and that HIV-positive women who are 
not eligible for this therapy and their exposed infants have 
one of two prophylactic combination regimens to prevent 
transmission from mother to child.79,81 Furthermore, for 
the ﬁ rst time, antiretroviral drug prophylaxis was 
recommended during breastfeeding in settings where 
breastfeeding is the safest feeding option for infants.
Worldwide, progress has been made in scaling up 
PMTCT in resource-poor settings. About 370 000 children 
born to mothers with HIV infection were newly infected 
with HIV in 2009—a decrease of 24% from 2004.52 Testing 
coverage of pregnant women also improved from 7% in 
2005 to 26% in 2009, and 53% of HIV-positive women in 
low-income and middle-income countries received anti-
retroviral drugs to prevent mother-to-child trans mission 
in 2009—an increase from 45% in 2008, and 15% in 
2005.67 However, a recent demographic model showed 
that even if new HIV infections in women of reproductive 
age were halved, the unmet need for contraception was 
eliminated, the new guidelines had 90% coverage, and 
the duration of breastfeeding was reduced to 12 months, 
the reduction in new infections in children and the rate of 
mother-to-child transmission would still fall short of 
UNAIDS’ objectives by 2015.78 Thus, focus on all four 
prongs of WHO’s PMTCT strategy is essential.
Understanding women’s fertility intentions and the 
expansion of family planning services to HIV-infected non-
pregnant and pregnant women is important to address the 
second prong of WHO’s PMTCT strategy. The provision of 
contraception to women with HIV who do not want to 
become pregnant can be more cost eﬀ ective than the 
provision of PMTCT services.82 In addition, stimulation of 
demand and strengthening of delivery of services are a 
major focus of research attention, with particular emphasis 
on prevention of leakage at every step in the cascade. Low 
use of antenatal-care services, poor provider knowledge, 
low coverage of HIV testing, and poor patient 
documentation and tracking systems have hindered 
translation of research ﬁ ndings into routine practice.83 Of 
the 25 highest burden countries, only ten had moved from 
single-dose nevirapine to more eﬀ ective combination 
regimens for PMTCT by 2009, although WHO has rec-
ommended this approach since 2004.84 Furthermore, the 
emphasis on immunological monitoring to establish ART 
eligibility will need substantial scale-up of CD4 cell testing 
(in 2008, only 24% of pregnant women with HIV received 
a CD4 cell count85) and complementary implementation 
research to identify models of service delivery that 
minimise attrition in view of the added com plexity of 
combination regimens and immunological monitoring.86
Male circumcision
In the past 3 years, further studies have conﬁ rmed that 
VMMC reduces risk of HIV acquisition in men.87–89 By 
contrast, the question of the protective eﬀ ect of VMMC 
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for women has been debated. Although the beneﬁ t to 
women of their male partner not acquiring HIV is 
obvious, whether voluntary male circumcision has 
beneﬁ t for the woman if her partner is already positive is 
unclear. Findings from one randomised controlled trial 
suggested no immediate beneﬁ t of VMMC in reduction 
of transmission from infected men to their female 
partners,90 but an older observational study91 and a recent 
prospective study92 showed reductions of up to 46% in 
male-to-female transmission. These data have led to 
revised calculations of the potential population-level 
eﬀ ect of VMMC, with estimates of infection reductions 
for men and women as high as 28% in Zimbabwe.93 
These potential beneﬁ ts are ampliﬁ ed by reductions in 
the risk of acquisition and transmission of human 
papillomavirus, the precursor to cervical cancer, in 
men,94–96 although research is conﬂ icting about the eﬀ ect 
of VMMC on acquisition of Trichomonas vaginalis.97,98
Since 2008, district-level scale-up eﬀ orts in Kenya99 and 
Tanzania100 have shown that VMMC can be delivered at a 
pace and scale consistent with reaching population-level 
eﬀ ect. However, although ecological studies101,102 of 
populations in which traditional male circumcision is 
common provide some evidence for population-level 
outcomes, no data are available for how great an eﬀ ect 
this scale-up will have on the epidemic. Eﬀ orts will 
beneﬁ t from implementation research, such as how best 
to create demand, increase levels of HIV testing, and 
maximise adherence to the 6-week period of sexual 
abstinence after surgery. Research into non-surgical 
methods103,104 will also provide valuable options in settings 
where surgical staﬀ  are scarce.
Although there are examples of rapid and intensive 
scale-up, the same has not happened in some high-burden 
regions and countries. In many countries, policy makers 
have been slow to support VMMC.105,106 This reluctance 
may stem from perceptions that support is biased towards 
particular religious groups, that its advocation will lead to 
widespread behavioural disinhibition, and that rollout will 
strain already overburdened health systems.105,107 Indeed, 
although rapid scale-up seems best accomplished by 
assembly of one-time teams of health-care staﬀ ,99,100 
elements of the health system that are weak in many low-
resource countries are still heavily relied on, highlighting 
the need for task shifting and further innovation into 
issues related to supply-chain, transportation, and 
ﬁ nancing. These real and perceived barriers have slowed 
the rollout of VMMC, but indications such as dedicated 
funding within PEPFAR bilateral budgets show that 
support is growing.
Structural and behavioural interventions
Structural interventions 
Structural interventions can reduce high-risk behaviours, 
STIs, and known mediators of risk, including gender 
inequality and intimate partner violence.108–110 Recently, 
studies of cash transfer programmes have strengthened 
the hypothesis that economic instability and poverty drive 
risk behaviour in young women. A randomised trial in 
Malawi111,112 showed that girls receiving a cash transfer 
(either unconditional or linked to school attendance) had a 
lower prevalence of HIV and HSV-2 infections than did 
controls (60% and 75% lower, respectively), because of 
delayed sexual debut, fewer and younger partners, less 
sexual activity, and reduced transactional sex. A randomised 
trial in Tanzania113 linking cash transfers to remaining free 
of STIs suggested that men and women receiving 
incentives had a 25% lower incidence of infection than did 
controls. By contrast, another programme in Malawi114 that 
paid men and women to maintain their HIV-negative 
status for 1 year, noted no eﬀ ect, although size and timing 
of the incentive might have been limiting factors. The 
preliminary results of these studies suggest that ﬁ nancial 
security could aﬀ ect sexual behaviour, and that the 
promotion of economic empowerment and sustainable 
livelihoods might be key to reduction of HIV risk.115
Legislative reforms, reducing stigma and discrimination, 
and enhancing social capital are important structural 
interventions for a range of populations, including sex 
workers, men who have sex with men, and injecting drug 
users.3 A systematic review showed that policy-level 
support and empowerment strategies for sex workers 
can improve accept ability, adherence, and coverage of 
HIV-prevention program mes.116 Similarly, modelling 
suggests that approaches designed to mitigate the 
harmful eﬀ ects of drug use, such as needle and syringe 
exchange programmes, medication assisted treatment 
for substance misuse, and other interventions, could 
substantially curtail epidemics related to injecting-drug 
users, particularly when implemented alongside non-
discriminatory laws and rights-based interventions.117,118
Further research is needed to guide replication and scale-
up of promising programmes, and to document how dif-
ferent structural interventions aﬀ ect patterns and pathways 
of risk. Although structural interventions  are diﬃ  cult to 
evaluate in randomised trials,8 important methodological 
innovations and lessons are emerging with new support 
from donors.3,119,120 Further research should explore key 
elements of economic interventions such as microﬁ nance 
(leading to indepen dence and more choice and control 
over sexual partners and behaviours), including the addi-
tional beneﬁ ts of training or community mobilisation.109,121 
For cash transfer programmes, under standing which 
behaviours can be incentivised is important, as is the size, 
frequency, and conditionality of transfers.122 Finally, the 
importance of structural interventions that address cultural 
norms, gender and economic inequalities, migrant labour, 
and other factors underlying individual behaviour (eg, con-
current partnerships) is a substantial area of exploration.
Behavioural interventions  
Coates and colleagues4 concluded that behavioural 
strategies were essential, but not suﬃ  cient, components 
of comprehensive HIV prevention and that “behavioural 
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strategies themselves need to be combinations of 
approaches at multiple levels of inﬂ uence”. Although 
estimates have suggested a decreased incidence of HIV 
in 33 countries, along with reduced sexual-risk behaviour 
in young people,52,123 weaknesses in the availability of both 
programme evaluation and behavioural and epidemi-
ological data make causal attribution of these reductions 
to HIV prevention programming diﬃ  cult. For example, 
in Zimbabwe, careful analysis has suggested that 
incidence declines with behaviour change,7,8 but this 
ﬁ nding contrasts with a randomised controlled trial of a 
multipronged prevention intervention in one region of 
Zimbabwe that failed to show an eﬀ ect (potentially 
because of timing or insuﬃ  cient power).124
In the generalised epidemics of southern Africa, much 
attention has focused on overlapping or concurrent 
partnerships; albeit with controversy.125,126 Although there 
is no disagreement that multiple concurrent partnerships 
contribute to risk for HIV transmission, and thus should 
be subject to HIV prevention programming responses,127 
the normative hold of concurrency makes such 
partnerships diﬃ  cult to address directly. Regional media 
campaigns in South Africa suggest some preliminary 
eﬀ ects on some risk behaviours, but no eﬀ ects (as yet) for 
multiple partnerships.128
Behavioural strategies for prevention in men who have 
sex with men have shifted from generic strategies to ones 
that are tailored toward the serostatus of both partners. A 
review noted increased incidence in men who have sex 
with men in many high-income countries, and the 
prevalence of seroadaptive behaviours in these popu-
lations.129 14–44% of HIV-positive men who have sex with 
men, and 25–38% of those who are HIV negative, reported 
restricting unprotected anal intercourse to seroconcordant 
partners, and 14–35% and 6–15% of men who are HIV 
positive or negative, respectively, who have sex with men 
reported selecting insertive or receptive sex on the basis 
of HIV status. Evidence is available that men who have 
sex with men use partner viral load as another determinant 
in behaviours to reduce risk,130 with added attention to 
this strategy after the so-called Swiss statement that HIV 
transmission in the context of fully suppressed viral load 
and absence of STIs was unlikely.131 
Behavioural prevention for injecting-drug users con-
tinues to focus on strategies aimed at mitigating the 
harmful impacts of drug use, in order to reduce risk 
behaviour (needle sharing) and HIV incidence.117,132 
Impor tantly, most studies have noted that the eﬀ ect of 
these programmes is greatly enhanced with combin-
ations of structural (eg, law reform), biomedical (eg, 
ART), and beha vioural (eg, needle and syringe 
programmes) approaches.117
Diﬃ  culties in measurement of HIV incidence, together 
with the well documented problems in self-report of sexual 
behaviour, mean that the “gold standard” of evidence for 
behavioural interventions is unlikely to be reached soon.5 
However, large-scale behavioural change is clearly central 
to reduction of incidence, and behavioural interventions 
are crucial in ampliﬁ cation and facilitation of other 
prevention approaches, including driving demand for 
HIV services such as HIV testing, VMMC, PMTCT, and 
treatment. Assessment of the eﬀ ect that these programmes 
have on service uptake might be useful both alone and as 
a proxy for eﬀ ect on HIV incidence. Key questions for 
implementation of behavioural interventions concern the 
challenge of bringing community-based programmes to 
scale while maintaining quality and a better appreciation 
of the balance between local adaptability and ﬁ delity.
Discussion
In the past year, HIV prevention has changed substantially 
and several eﬃ  cacious interventions have reinvigorated 
the preventive science community (table). The value of 
prevention with antiretroviral drugs for individuals with 
and without HIV has emphasised the overlap of treatment 
and prevention, and reinforces the need for integrated 
strategies for epidemic control. No longer is it acceptable 
to consider expenditures for treatment and prevention 
separately; the challenges of sustainably ﬁ nancing 
epidemic control apply equally to both.134 New preven-
tion approaches demand increased inter disciplinary 
approaches within the prevention com munity. 30 years 
into the HIV/AIDS epidemic, clearly the separation of 
biomedical and behavioural prevention is outdated and 
ineﬃ  cient. For example, the successes of biomedical 
interventions, such as pre-exposure prophylaxis and 
treatment for prevention, will rely as much on the ability 
Eﬀ ectiveness of prevention intervention Number of trials
Positive eﬀ ect Adverse eﬀ ect No eﬀ ect
Behavioural ·· ·· 7 7
Structural: microﬁ nance, CCTs 1*111 ·· 2108,114 3
Diaphragm use ·· ·· 1 1
Topical agents (microbicides)
Non-ARV based ·· 1 11 12
ARV-based PrEP 135 ·· ·· 1
Systemic, oral PrEP 139 ·· 2†133,‡40 3
Treatment as prevention 147 ·· ·· 1
Male circumcision 3 ·· 1 4
STI treament 1 ·· 8 9
Vaccine 1 ·· 3 4
Total trials 9 1 35 45
Results of 43 phase 2b or phase 3 randomised trials of 45 interventions to prevent the sexual transmission of HIV. 
Adapted from Padian and colleagues,5 and updated with results of six trials since July, 2010 (the period since the last 
review).35,39,40,47,111,114 See webappendix for full list of references for each category. Positive eﬀ ect was when the intervention 
signiﬁ cantly reduced the risk of HIV in the intervention group compared with the control group; adverse eﬀ ect was when 
the intervention signiﬁ cantly increased the risk of HIV in the intervention group compared with the control group; and 
no eﬀ ect was when the intervention showed no signiﬁ cant eﬀ ect (positive or adverse), thus the null hypothesis could not 
be rejected. CCT=conditional cash transfer. ARV=antiretroviral. PrEP=pre-exposure prophylaxis. STI=sexually transmitted 
infection. *Study, which has not yet been published in peer-reviewed publications, did not measure HIV incidence but 
showed diﬀ erences in HIV prevalence. †Premature closure of the trial substantially reduced study power. ‡FEM-PrEP 
study prematurely closed because of futility after interim analyses revealed no protection against HIV. Table reproduced 
with permission from Wolters Kluwer Health.
Table: Interventions to prevent the sexual transmission of HIV
See Online for webappendix
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of an intervention to enhance adherence (behavioural), 
as on the drugs’ pharma cokinetics (biomedical).
A signiﬁ cant change in new prevention ﬁ ndings is the 
promise for more prevention strategies whose initiation 
and implementation is under the control of women. For 
example, topical pre-exposure prophylaxis, especially 
when used as prophylaxis by women, has the potential to 
change the gender dynamic in the epidemic enormously. 
A vaccine would be the great equaliser, presumably 
protecting men and women indistinguishably. Addition-
ally, growing research has shown that structural 
interventions including conditional cash transfers have 
the potential to reduce risk behaviours as well as STIs and 
HIV. Given that HIV in much of Africa disproportionately 
aﬀ ects women,52 this is a signiﬁ cant change in approach 
and holds substantial promise for future implementation. 
Until recently, all available prevention technologies, such 
as male and female condoms and male circumcision, 
required male initiation or acceptance, or both.
The central role of prevention based on antiretroviral 
drugs has emphasised the importance of adherence-
independent approaches. Perhaps more importantly, the 
promise of such prevention has indicated that ethical and 
policy issues are as important as research into 
eﬀ ectiveness. In view of scarce resources, the need to 
prioritise those who get antiretroviral drugs (pre-exposure 
prophylaxis or treatment for prevention), and consider 
the burden of distribution in view of frail health systems, 
calls for a diﬀ erent type of research that focuses on the 
balance between eﬃ  ciency and equity and issues related 
to implementation science. An essential question is how 
a country’s health service could maintain antiretroviral 
therapy in legions of healthy patients with high CD4 cell 
counts mainly for prevention beneﬁ ts to partners, when it 
is not able to initiate and maintain high retention of those 
with low CD4 cell counts who need ART for survival.
HIV testing, VMMC, and PMTCT research should 
focus on implementation science issues related to 
eﬃ  cient and eﬀ ective scale-up, including methods to 
increase demand, uptake, and adherence, and those to 
optimise and strengthen elements of the health system, 
including procurement, supply chain, transportation, 
and sustained ﬁ nancing. 
As we move forward, we cannot fail to assess impact.135 
Although methodological challenges such as the absence 
of a reliable incidence assay, the lack of naive control 
groups, and no suitable surrogates for HIV complicate 
evaluation, the time has come to require that programmes 
be implemented so that impact can be assessed. 
Concurrent advances in methods of evaluation have been 
made to support this eﬀ ort.136 This is essential in order to 
ensure transparent and unequivocal results that can 
demonstrate the eﬀ ect of the programme being evaluated 
and just as importantly, that can inform the global eﬀ ort to 
combat HIV/AIDS.
The future of HIV prevention is in operational isation, 
implementation, and assessment of combination 
preven tion programmes.1,137 However, combination inter-
ventions have their challenges, including adaptation and 
replication of complex and multifaceted prevention 
programmes whose successes might depend on subtle 
factors of context or programme delivery. For example, 
the develop ment of one integrative package that 
suﬃ  ciently incorporates local ownership of AIDS 
responses is unlikely; speciﬁ cally, the need to tailor the 
combination to local epidemiology remains paramount. 
Our challenge is to carefully select a group of eﬀ ective 
interventions that together have an increased chance of 
success by comple menting each other to achieve the 
elusive goal of changing the course of the HIV epidemic.
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